Update prognostic potency of surfactant protein D (SP-D) in the COVID-19 landscape: an In-depth meta-analytical exploration.

INTRODUCTION

Surfactant Protein D (SP-D), a key component of the innate immune system, has attracted significant interest for its potential role in the pathophysiology and prognosis of COVID-19. This systematic review and meta-analysis aim to clarify the prognostic importance of SP-D levels in COVID-19 patients.

METHODS

A comprehensive literature search was conducted using PubMed, Web of Science, Cochrane Library, Scopus, EMBASE, and Google Scholar, covering studies published from January 2000 to January 2024. The inclusion criteria focused on studies measuring SP-D levels in the serum or plasma of COVID-19 patients, comparing severe and non-severe cases. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using a random-effects model to assess overall effect sizes. Meta-regressions and subgroup analyses were performed to identify potential sources of heterogeneity, including patient age, assay techniques, and gender ratio.

RESULTS

The meta-analysis incorporated data from nine studies involving 5,410 COVID-19 patients. Elevated SP-D levels were significantly correlated with increased disease severity, yielding an SMD of 0.642 (95% CI: 0.314 to 0.870;  = 0.012).

CONCLUSION

This meta-analysis confirms the prognostic significance of SP-D in the context of COVID-19. Elevated SP-D levels are associated with severe disease outcomes, highlighting its potential as a prognostic biomarker.